Corbus Pharmaceuticals Starts Phase 3 Cancer Study, Weighs Next Steps for Obesity Drug

Corbus Pharmaceuticals (NASDAQ:CRBP) has begun a Phase 3 study of its lead cancer drug in second-line oropharyngeal cancer and is considering further development of an obesity treatment that recently completed a Phase 1b study, CEO Yuval Cohen said during a Jefferies fireside chat.

Cohen described the cancer drug, CRB-701, as the core of Corbus’ oncology business. The Nectin-4-targeting antibody-drug conjugate, also called sutantatug envedotin or Suta E, is being tested in the TEMPO-1 registrational study. The company’s other asset is a peripherally restricted CB1 inverse agonist for obesity.

Cancer Study and Approval Strategy

Corbus is pursuing an accelerated approval strategy in second-line oropharyngeal cancer based on overall response rate, with the study continuing to assess overall survival for final approval, Cohen said. He said the company had alignment with the Food and Drug Administration but declined to disclose specific details.

Cohen said the study’s assumptions include an approximately 20% response rate in the control arm. He said clinical experts consider a response rate above 30% desirable and actionable in second-line head and neck cancer, while the bar for a clinically useful effect in frontline treatment is above 50%.

TEMPO-1 enrolls patients based on the anatomical location of their cancer rather than HPV status, although Cohen said stratification is important to ensure the study population reflects patients seen in practice. He said one of the company’s best responders in earlier testing was HPV-negative.

Asked about a potential biologics license application in the second half of 2028, Cohen said the key would be obtaining response data with sufficient follow-up. The data would need to be robust and directionally promising enough to support a submission, he said.

Competition and Safety

Cohen said he expects minimal, if any, effect on TEMPO-1 enrollment from a potential frontline move by the competing treatment referred to as peto. He said Corbus’ enrollment should be completed or largely completed by the time that treatment reaches the market.

For a potential frontline role for CRB-701, Cohen said Corbus would need to compare its results in oropharyngeal patients with peto’s results in a similar population. He said a sufficiently large efficacy difference could create an opportunity for both treatments to coexist.

On safety, Cohen said ocular events associated with CRB-701 include keratitis and dry eye. He said such effects tend to occur early and are almost always resolvable, with management including eye drops, temporary treatment interruptions and dose reductions.

Referring to head and neck safety data at the 3.6 mg/kg dose, Cohen said he recalled that approximately one-third of patients had an interruption and that interruptions averaged about one additional week. He pointed to the company’s ASCO poster for the detailed data.

Obesity Program

Cohen said feedback from clinical experts at ObesityWeek was encouraging on the obesity drug’s efficacy and safety. He said experts expressed interest in combining it with orforglipron and in seeing results from a longer study.

Cohen said irritability observed in the CANYON-1 study was mild, generally occurred early, resolved and did not lead to treatment discontinuations. He added that the events were not dose-dependent.

Looking ahead to a possible one-year study, Cohen said the company and the experts it consulted expect weight loss above 10%, potentially between the levels seen with orforglipron and oral Wegovy. He presented that as an assumption about future results, not an observed outcome.

About Corbus Pharmaceuticals (NASDAQ:CRBP)

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biotechnology company based in Norwood, Massachusetts. It develops investigational medicines, with current research focused on cancer and obesity. Its oncology pipeline includes CRB-701, an antibody-drug conjugate designed to target Nectin-4, and CRB-601, an antibody targeting the αvβ8 integrin. The company is also developing CRB-913, an investigational drug candidate designed to act on the cannabinoid CB1 receptor for obesity treatment. These candidates are in development and are not approved medicines.